GlassScriptPhysician profile
Hannah Hirsch Counts
NPI 1639845589
$8,288.43
in general payments reported to CMS, 2019-2025
30 companies · $2,601 in 2025
The $2,601 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $1,742 · 2023: $1,642 · 2024: $2,128 · 2025: $2,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,041 · Travel and Lodging: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.92 |
| Travel and Lodging | $330.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,785.36 | 2022-2025 | Watchman Access System, Watchman Flx, General - Vascular Intervention |
| Amgen INC. | $1,246.33 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,054.30 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $677.29 | 2021-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $509.27 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $434.06 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.33 | 2022-2025 | Jardiance |
| Edwards Lifesciences Corporation | $325.46 | 2022-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $260.17 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $219.31 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $143.11 | 2023-2025 | Onpattro |
| Novo Nordisk INC | $129.70 | 2024-2025 | Wegovy |
| Esperion Therapeutics, INC. | $126.71 | 2021-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.31 | 2022-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $118.47 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $109.83 | 2022-2023 | Verquvo |
| Abiomed | $108.79 | 2024-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $85.88 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $77.81 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $59.35 | 2022-2025 | |
| Atricure, INC. | $46.20 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Scpharmaceuticals INC. | $37.35 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $37.07 | 2023 | Arcalyst |
| Cvrx, INC. | $28.19 | 2024-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $26.79 | 2023 | Optimizer |
| Philips North America LLC | $25.75 | 2025 | Event |
| Abbott Laboratories | $22.37 | 2025 | Jot Dx |
| Genzyme Corporation | $20.45 | 2023 | |
| Altathera Pharmaceuticals LLC | $17.44 | 2025 | Sotalol Hydrochloride |
| Corcept Therapeutics | $15.98 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Counts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.